Trinity Delta view: HUTCHMED’s strategy to accelerate its path to profitability and bring first-in-class and best-in-class targeted therapies to the market globally has been boosted by the Takeda fruquintinib partnership. This broadens fruquintinib’s development and commercial potential and gives HUTCHMED greater bandwidth to further maximise the commercial traction underway in China, and to progress its late-stage pipeline. Our last published HUTCHMED valuation was $5.51bn ($31.89 per ADS), £4.6bn and HK$43.1bn (531p or HK$49.83 per share), which was pre the Takeda deal and does not reflect FY22 results.
